Partnerships, product milestones and the science behind connected respiratory care: from RS01X smart inhaler validation to real-world inhaler-technique results. For press enquiries, get in touch.
At Respiratory Drug Delivery 2026 we presented a pharmacy-led service evaluation in adults with asthma or COPD. With Respiro, nearly three in four improved their inhalation technique, and the gains held across three different inhalers and the parameters that matter most.
Read the resultsWith ARTES 4.0 and PNRR backing, we brought CFD simulation and automation to the next generation of inhaler sensors: up to 40% less development time, so better connected hardware reaches patients sooner.
Read moreA peer-reviewed study tested how accurately RS01X reads each inhalation against a laboratory reference. Across 97 people with asthma, COPD and healthy lungs, agreement was near-perfect.
Read moreA cluster randomised trial across 18 pharmacies found patients using Respiro improved their asthma control about twice as much as counselling alone (ACT +5.9 vs +2.9, p=0.007).
Read moreWe joined SIDERA^B, a Regione Lombardia programme for integrated home care and assisted rehabilitation: extending connected respiratory support beyond the clinic.
Read moreWe won regional investment through Tech Fast Lombardia: support for our growth and new roles as we scaled connected respiratory care from Milan.
Read moreWe signed a global commercial agreement to launch RS01X: the digitally-connected evolution of Plastiape's widely used RS01 single-dose inhaler.
Read moreAn early Respiro service evaluation showed better medication adherence and health outcomes in asthma: among the first real-world evidence behind the platform.
Read moreAt Drug Delivery to the Lungs 2018, an accuracy study showed Respiro Sense reading key inhalation measures with around 90% accuracy or better, fitted to Merxin's dry-powder inhalers.
Read moreGermany's KBV (the national association of statutory health-insurance physicians) selected Respiro through its open call for innovation in care.
Read moreWe were recognised among Germany's top three digital-health companies of 2018: a finalist for the Health-I Award.
Read moreWe partnered with the Luz Saúde healthcare group to bring connected respiratory monitoring into routine clinical practice.
Read moreRespiro received CE marking for use with three widely used inhalers: our first step into regulated medical-device territory, and the foundation the platform is built on today.
Read moreWe closed a strategic investment round led by Sanner and Breed Reply: strategic investors in devices and connected products, backing the Respiro platform's next phase.
Read moreRespiro took first prize at the IBM Watson AI XPRIZE Milestone Awards: early recognition for turning inhaler data into clinical intelligence with AI.
Read moreA selection of independent coverage of Amiko and Respiro.
External coverage links to the original publishers; headlines belong to them. Listing does not imply endorsement.
For press enquiries, partnership announcements or a briefing on the platform, our team is happy to talk.